688098.SHG Shanghai Shen Lian Biomedical Corp
- Market cap
- CNY 3.02B
- P/E
- -
- P/B
- 2.10x
- ROE
- -1.0%
- Dividend yield
- 0.01%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 688098.SHG undervalued?
Graham numberThe Graham number of Shanghai Shen Lian Biomedical Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shanghai Shen Lian Biomedical Corp fundamental analysis
No fundamental analysis for Shanghai Shen Lian Biomedical Corp yet.
Shanghai Shen Lian Biomedical Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shanghai Shen Lian Biomedical Corp
Shanghai Shen Lian Biomedical Corporation engages in the research, development, production, and sale of veterinary biological products in China. The company offers swine vaccines, ruminant vaccine, diagnostic reagents, and pet biological products. It also provides monoclonal antibody drug for HIV treatment, anti-allergy anti-IgE monoclonal antibody drug, and anti-herpes simplex virus monoclonal antibody drugs. In addition, the company offers foot-and-mouth disease vaccines f…
Full company profileShanghai Shen Lian Biomedical Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shanghai Shen Lian Biomedical Corp annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 268M | 302M | 275M | 254M | 338M | 358M | 329M | 301M | 303M | 288M | 255M |
| Gross Profit | 209M | 241M | 221M | 209M | 283M | 271M | 247M | 214M | 183M | 288M | 159M |
| Operating Income | 88.4M | 114M | 101M | 90.9M | 147M | 129M | 75.2M | 36.1M | -56.5M | -26.4M | 6.14M |
| EBITDA | 101M | 125M | 113M | 106M | 171M | 170M | 144M | 99.5M | 11.1M | 42.8M | -18.6M |
| Net Income | 73.5M | 98.7M | 87.6M | 78.0M | 130M | 110M | 61.1M | 31.5M | -44.7M | -19.1M | -14.1M |
| EPS | 0.77 | 0.30 | 0.26 | 0.21 | 0.31 | 0.27 | 0.15 | 0.08 | -0.11 | -0.05 | -0.03 |
| Balance Sheet | |||||||||||
| Total Assets | 608M | 692M | 1.01B | 1.45B | 1.51B | 1.60B | 1.61B | 1.59B | 1.55B | 1.54B | 1.57B |
| Total Liabilities | 142M | 143M | 181M | 166M | 118M | 125M | 108M | 86.9M | 128M | 143M | 166M |
| Shareholders' Equity | 465M | 549M | 832M | 1.28B | 1.40B | 1.48B | 1.50B | 1.49B | 1.41B | 1.39B | 1.40B |
| Cash & Short-term Investments | 165M | 146M | 384M | 156M | 587M | 468M | 358M | 207M | 190M | 122M | 62.2M |
| Total Debt | - | 27.7M | 30.0M | 30.0M | 652K | 514K | 446K | 1.25M | 15.0M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 48.0M | 74.6M | 121M | 53.8M | 112M | 90.1M | 9.09M | 3.53M | 89.4M | 33.1M | - |
| Capital Expenditure | 116M | 103M | 78.8M | 104M | 164M | 188M | 93.1M | 130M | 84.9M | 45.2M | 21.7M |
| Free Cash Flow | -67.7M | -28.8M | 42.3M | -50.3M | -51.8M | -98.0M | -84.0M | -126M | 4.45M | -12.2M | -59.7M |
| Ratios | |||||||||||
| ROE | 15.8% | 18.0% | 10.5% | 6.1% | 9.3% | 7.5% | 4.1% | 2.1% | -3.2% | -1.4% | -1.0% |
| ROA | 12.1% | 14.3% | 8.6% | 5.4% | 8.6% | 6.9% | 3.8% | 2.0% | -2.9% | -1.2% | -0.9% |
| Net Profit Margin | 27.4% | 32.7% | 31.8% | 30.7% | 38.3% | 30.7% | 18.6% | 10.5% | -14.7% | -6.6% | -5.5% |
| Debt to Equity | - | 0.05x | 0.04x | 0.02x | 0.00x | 0.00x | 0.00x | 0.00x | 0.01x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shanghai Shen Lian Biomedical Corp dividends
- Dividend yield
- 0.01%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jun 14, 2024
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 266K | 0.00 | - |
| 2024 | CNY 14.3M | 0.04 | - |
| 2023 | CNY 32.8M | 0.08 | 104.0% |
| 2022 | CNY 37.0M | 0.09 | 60.5% |
| 2021 | CNY 41.0M | 0.10 | 37.2% |
| 2020 | CNY 32.8M | 0.08 | 25.3% |
| 2019 | CNY 28.8M | 0.08 | 36.9% |
| 2018 | CNY 10.5M | 0.03 | 12.0% |
| 2017 | CNY 15.8M | 0.05 | 16.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Shanghai Shen Lian Biomedical Corp
- Insiders 55.79%
- Institutions 0.15%
- Public & others 44.06%
- Shares outstanding 411M
- Free float 223M
Shanghai Shen Lian Biomedical Corp company profile
- Company name
- Shanghai Shen Lian Biomedical Corp
- Ticker
- 688098.SHG
- ISIN
- CNE100003P17
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 376
- Fiscal year end
- December
- Address
- No. 48 Jiangchuan East Road, Shanghai, China, 200241
- Phone
- 86 21 6125 7979
- Website
- slbio.com.cn
About Shanghai Shen Lian Biomedical Corp
Shanghai Shen Lian Biomedical Corporation engages in the research, development, production, and sale of veterinary biological products in China. The company offers swine vaccines, ruminant vaccine, diagnostic reagents, and pet biological products. It also provides monoclonal antibody drug for HIV treatment, anti-allergy anti-IgE monoclonal antibody drug, and anti-herpes simplex virus monoclonal antibody drugs. In addition, the company offers foot-and-mouth disease vaccines for pigs, cattle, and sheep; and porcine circovirus type 2 subunit vaccines. Shanghai Shen Lian Biomedical Corporation was founded in 2001 and is headquartered in Shanghai, China.
Shanghai Shen Lian Biomedical Corp management
7- Mr. Dongsheng NieChairman of the Board of Directors and Director of R&D Center · born 1960
- Mr. Zhen ZhangEmployee Representative Director, GM & Core Technical Personnel · born 1980
- Mr. Xun LiuFinancial Director · born 1991
- Mr. Bo YinTechnical Director · born 1983
- Ms. Haixia YuBoard Secretary · born 1985
- Jie WuAccounting Supervisor
- Mr. Gui Jun MaCore Technician of R&D Center · born 1977